

S O U T H D A K O T A P H A R M A C I S T

IN THIS ISSUE

COVID-19 Resources: Where to Find Them
Spring District Meetings Move to Zoom
SDPhA Annual Meeting Registration



SPRING EDITION 2020



Our mission is to promote, serve and protect the pharmacy profession.

SOUTH DAKOTA PHARMACISTS ASSOCIATION

320 East Capitol, Pierre SD 57501
605-224-2338 // 605-224-1280 fax
www.sdpha.org

PRESIDENT

Lori Ollerich

PRESIDENT-ELECT

Dana Darger

VICE PRESIDENT

Kristen Carter

TREASURER

Melissa Gorecki

AT-LARGE BOARD MEMBERS

Bernie Hendricks, Jessica Strobl

EXECUTIVE DIRECTOR / EDITOR

Amanda Bacon
amanda@sdpha.org

IMMEDIATE PAST PRESIDENT

Erica Bukovich

SOUTH DAKOTA BOARD OF PHARMACY

4001 W. Valhalla Blvd. Ste. 106
Sioux Falls, SD 57106
605-362-2737 // www.pharmacy.sd.gov

PRESIDENT

Lenny Petrick

MEMBERS

Diane Dady, Cheri Kraemer,
Tom Nelson, Dan Somsen

EXECUTIVE DIRECTOR

Kari Shanard-Koenders

INSPECTORS

Paula Stotz, Tyler Laetch, Carol Smith

SUPPORT STAFF

Beth Windschitl, Rhea Kontos

PRESCRIPTION DRUG MONITORING PROGRAM

Melissa DeNoon, Director
Melanie Houg, Assistant

Calendar

APRIL

- 2 South Dakota Board of Pharmacy Meeting
Sioux Falls, SD 1–5 pm
- 2 Rosebud District Spring Meeting
Via Zoom, 7 pm
- 5 Mitchell District Spring Meeting
Via Zoom, 7 pm
- 7 Watertown District Spring Meeting
Via Zoom, 6:30 pm
- 8 Aberdeen District Spring Meeting
Via Zoom, 7 pm
- 12 Easter
- 14 Black Hills District Spring Meeting
Via Zoom, 7 pm
- 19 Mobridge District Spring Meeting
Via Zoom, 7 pm
- 30 Sioux Falls District Spring Meeting
Via Zoom, 6 pm

MAY

- 1 Award Nominations due to SDPhA Office

JUNE

- TBA South Dakota Legislature – Special Session

SEPTEMBER

- 25–26 SDPhA Annual Meeting
Registration is Open (Keep your fingers crossed!)
Brookings, SD
www.sdpha.org/annual-convention

Please note: If you are not on our mass e-mail system check our website periodically for district meetings and other upcoming events. They will always be posted at: www.sdpha.org.

CONTENTS

FEATURES

- 4 Director's Comments
- 5 President's Perspective
- 6–9 South Dakota Board of Pharmacy
- 10 SDSU College of Pharmacy and Allied Health Professions
- 11 Academy of Student Pharmacists
- 12–13 Pharmacy Technicians University (PTU)
- 14 Coronavirus (Covid-19) Update
- 15 South Dakota Association of Pharmacy Technicians
- 16 South Dakota Society of Health System Pharmacists
- 17 C & L and District Contribution Form

134TH ANNUAL CONVENTION

- 18–19 Registration Form
- 20–21 Exhibitor / Sponsorship Form

CONTINUING EDUCATION

- 22–27 Continuing Education for Pharmacists

ADVERTISERS

- 28 Team of the Year Award
- 29 Pharmacists Mutual Companies
- 30 Classifieds

Support of our advertisers makes it possible to bring you news in the form of a Journal. When making purchases and other equal factors, please give our advertisers the support they deserve.

The South Dakota Pharmacist is published quarterly: January, April, July, and October. Opinions expressed do not necessarily reflect the official positions or views of the South Dakota Pharmacists Association.

Director's COMMENTS

Amanda Bacon // Executive Director



Dear Friends,

What a difference a few months can make. The reality of the COVID-19 pandemic has changed not only how and where (for some) we do our jobs each day, but has also found many of us attempting to educate our children from home, wondering whether there's yet toilet paper or flour on the store shelves, and praying we've left no stone

unturned in our efforts to keep our patients and staff safe. We are certainly in uncharted territory. Disruptive is an understatement. Especially for our retail pharmacists, where quite literally everything from our business models to how we interact with patients has been turned upside down.

But dear friends – I have never been prouder to represent you than I am right now. You are unsung heroes – who keep showing up and rising to the litany of new challenges placed before you each and every single day.

You are innovative.

You are bold.

You are brave.

And you are heroes.

I've exchanged more emails, calls and text messages with new pharmacists and "old pros" in the past weeks than I can count. Sometimes those are about brainstorming solutions, or being another set of eyes and ears to help walk through the current guidance on things. Sometimes it's just to talk about what's happening – in the world or the world that is their practice setting.

I often feel like I don't have as many answers as I'd like. But I've never been afraid to wade into the muck to search for them. The stink-out-loud reality right now however, is that sometimes there aren't any. But I can promise you we don't stop looking. We're fully engaged at the federal and state level where appropriate on your behalf. We're in constant communication with the Board of Pharmacy – working together on things we know you need to do your jobs, keep your doors open, and safely serve your patients. Some of that work may be complete and out to you by the time this Journal hits your inbox. Some of it may take longer. Either way, we won't stop working.

We strongly encourage you to connect to our [SDPhA – Member News and Announcements](#) Facebook Group if you haven't already. I'm giving daily updates there, as well as sending out emails to everyone as appropriate. Things happen and change around this at the speed of light, and we're working hard to ensure we're keeping you up-to-date on what you need to know. You've also built a [COVID-19 Resource page on our website](#). We're updating that as needed as well.

District meetings are also on the way – by the time you read this, some will have already taken place. These meetings will all take place via Zoom this year, so please watch your email and the SDPhA—Member News and Announcement page to make sure you have the login information. If you have a phone or computer, you can participate. This has all been a new adventure for us, so we appreciate your patience and consideration as we work together with your district presidents to get these off the ground.

Finally – keep the emails, phone calls and messages coming. We will get through this. I am 100% convinced that we will come out the other side stronger together.

Please take care and be well,

AMANDA BACON

SDPhA Executive Director

President's PERSPECTIVE

Lori Ollerich // SDPhA Board President



Greetings from SDPhA!

As the Greek philosopher Heraclitus said, "Change is the only constant in life." Especially these last few weeks, truer words have never been spoken. It seems like with the recent development of the COVID-19 pandemic, guidelines and recommendations are changing from day to day, sometimes hour by hour. I want to

give a big shout out to all of you that have been putting in long days and sleepless nights to ensure the safety of your patients, staff and communities – your efforts do not go unnoticed. You are heroes (even if you wear white coats instead of capes). I was hoping to be able to be writing to you on my flight home from the APhA Annual Meeting in Washington DC, but as that was cancelled (along with a lot of your spring meetings and conferences), here I am from my couch in PJ's on a Monday night.

I would like to take just a minute of your time to update you on some of the recent SDPhA activities as well as some potential upcoming events the association has scheduled.

SDPhA hosted legislative days in Pierre the last week of January. A big THANK YOU goes out to everyone that participated to make the event a success. This is one of the highlights of our year and gives both pharmacists and students a wonderful opportunity to engage in the legislative process. Kudos to Amanda for the weekly updates during session. If you DID NOT receive them, please let us know so we can update your information. As always, your contributions to the C&L fund make all of this possible, so thank you for your continued donations (and if you haven't donated this year, it's not too late – especially if you haven't spent your tax refund yet!).

Spring district meetings will look different this year. While we hope to hold most district meetings by way of "virtual meetings", some of you may not be able to meet due to extenuating circumstances within your communities. Please reach out to the association if there is anything you need, or anything we can do to help. We have set up a COVID-19 resources page on our website that you can reference if you have any specific issues/questions. We did download all award nomination forms onto our Members-Only Facebook page, so don't forget to get those submitted by May 1st.

Annual Convention may be in September, but between hand washings, we are already in full swing planning the event. Make this the year to come and enjoy a SDSU football game in Brookings on September 25-26. We have a great speaker line-up and hope we will all be able to gather together to celebrate our profession, reconnect with old friends, and take in some excellent CE (and did I mention football?!).

As always, we love to hear from you and encourage you to reach out to any of the association board members with any questions, concerns or ideas you may have at any time. We are looking forward to the time when we can get together again!

Respectfully,

LORI OLLERICH

SDPhA Board President

South Dakota BOARD of PHARMACY

Kari Shanard-Koenders // Executive Director



BOARD WELCOMES NEW REGISTERED PHARMACISTS/ PHARMACIES

Congratulations to the following six candidates who recently met licensure requirements and were licensed as new pharmacists in South Dakota: Amer Ahmed, James Coder, Jennifer Foy, Mary Foy, Brant Haase, and Rebekah Lee.

Three full-time pharmacy licenses were approved and issued during the period. They are Dakota Pharms, LLC dba Vilas, change of ownership; Gettysburg; Dakota Pharms, LLC, Vilas, change of ownership Highmore; and Lewis Family Drug dba Lewis Family Drug #50, Sioux Falls. There was one new part-time pharmacy. It was Lewis Drugs, Inc. dba Lewis Fifth Street, Sioux Falls.

COVID-19

Dear fellow pharmacists and technicians. I hope this finds you all safe and healthy, and making plans for the post COVID-19 world. The Board knows that this is a scary time for you and your businesses. We have provided routine board guidance and will continue to do so as needed. We will also work with you to reduce barriers caused by SD Board rules and regulations. We encourage you to not only be checking CDC guidance, but also the SD COVID-19 site for SD at <https://doh.sd.gov/news/Coronavirus.aspx> as it has a great deal of information including up to date statistics for our state. The CDC Healthcare Provider Guidance is also included on the site. Please let us know if we can do more to keep you informed or to make this easier on you. Working together, we can get through this. Stay safe and well!

SAVE THE DATE

Every seven years South Dakota takes its turn hosting the AACP/NABP District V Annual Meeting and we are up in 2021! We are thrilled that we have booked Custer State Park's State Game Lodge properties as our venue for the 83rd Annual meeting on August 4-6, 2021. Encompassing 71,000 acres in the beautiful Black Hills of South Dakota, Custer State Park is home to abundant wildlife and adventure; camping, hiking, biking, swimming, fishing, or relaxing, there's something here for everyone and the scenery in the park is exquisite. Plan to join us and bring the family! Early Reservations are encouraged, as this is high season for the Park. More information will be forthcoming. For motorcycle enthusiasts, the Sturgis Rally will hold their 81st Annual Rally August 6-15, 2021 an hour away in Sturgis. The hills will be alive!

PDMP UPDATE

by Melissa DeNoon, PDMP Director

A current PDMP 'hot button' issue is veterinary prescriptions. This is a complex issue beginning with how greatly veterinarian PDMP access and veterinarian data submission requirements vary from state to state. In SD, veterinarians do not have PDMP access and are not required to submit their dispensed controlled substance prescriptions to the database. Therefore, the only animal prescriptions in SD's PDMP are the ones dispensed by SD licensed pharmacies. There is also national controversy on how animal prescriptions should be entered in pharmacy dispensing software; should they be under a patient profile of the animal or of the owner? And if they are entered under the owner's pharmacy patient profile, is it considered 'appropriate access' if a veterinarian or a pharmacist queries the owner to see the animal's controlled substance prescription history? As these debates continue and to prepare in case SD PDMP law and rule regarding veterinary prescriptions changes in the future, these are best practices for all pharmacies to follow to bring consistency to how animal prescriptions appear in the SD PDMP:

1) Per ARSD 44:58:07:04 (3) (a), a dispensed controlled substance prescription shall include the name and address of the patient (or species and name and address of the owner if the patient is an animal). This means the pharmacy patient profile's first name field should contain the animal's name and species, i.e. Marcus Feline, and the last name field should contain the last name of the owner, i.e. Smith. The profile should also contain the owner's address and full name for reference.

2) The animal's date of birth is also very important; the date of birth needs to be verified with the veterinarian and the owner to ensure the correct date is being used in the pharmacy profile.

Unfortunately, diversion of animal prescriptions by pet owners is becoming a more prevalent problem. It is important to remember your pharmacist corresponding responsibility when filling animal prescriptions and verify these prescriptions with the prescriber as you would if you had a concern on a human prescription. The Board was recently made aware of a human overdose resulting from a dog's tramadol prescription. The prescription was for a large quantity so if you see animal prescriptions for large quantities of controlled substances, it may be prudent to query the animal in the PDMP and call the veterinarian if you have any concerns. The SD PDMP appreciates pharmacists' due diligence to this PDMP 'hot button' issue.



BOARD OF PHARMACY LISTSERV

By Tyler Laetsch, Inspector

The Board of Pharmacy Office now can use a listserv to send stakeholder email notifications. The office has been preparing the Listserv so that to all communications to our Pharmacists, Pharmacies, Wholesalers, Non-resident pharmacy community, and to interested stakeholders can go out on one listserv and we do not have to worry about missing someone. We will have a private list for pharmacist only emails which may address potential diversions or other pharmacist only communications. We will add those individuals and anyone who potentially accesses the list will need to be approved in office. The public listserv is for everyone! To subscribe to this please click the link below and follow the steps to get enrolled into the listserv. We will use the listserv to keep everyone notified of any changes to rules, meeting notices, renewal notices or any other items that need to be communicated to the whole pharmacy community. If you receive listserv emails, you may unsubscribe at any time. The listserv subscription link: <https://listserv.sd.gov/scripts/wa.exe?SUBED1=SDPHARMACYGENERAL&A=1>

South Dakota BOARD of PHARMACY

(continued)



OPIOID TRENDS IN SOUTH DAKOTA

The Board of Pharmacy is encouraged by the downward trend in opioid prescriptions dispensed to South Dakota patients and believes the PDMP is a key contributing factor as well as the many efforts throughout the state of South Dakota. Opioid prescriptions have decreased in the state over the last three years in all three parameters we measure: prescription count, total quantity, and total days of supply. South Dakota's website, www.avoidopioidsd.com, is an excellent resource for healthcare professionals and the public. The 'Key Data' page contains PDMP statistics and state statistics on drug related deaths, opioid related deaths, syndromic surveillance data, opioid use disorder treatment, and reported drug use and misuse. Navigating to 'About/Strategic Plan' provides links to multiple resources including one-page documents on the SD PDMP and the drug take-back program. The locator tool for all SD's take-back sites can be found at 'Take Action/Take Back Sites'. As of this writing, the Board has placed over 80 take back kiosks around the state! The Board of Pharmacy encourages pharmacists to utilize this valuable website and refer it to other healthcare professionals and your patients.

Respectfully submitted, for the Board,

KARI SHANARD-KOENDERS

SDBOF Executive Director

BOARD MEETING DATES

Check our website for the time, location and agenda for future Board meetings.

BOARD OF PHARMACY DIRECTORY

DIRECTOR, SD PDMP

Melissa DeNoon
melissa.denoona@state.sd.us

PHARMACY INSPECTORS

Tyler Laetch
tyler.laetch@state.sd.us
Paula Stotz
paula.stotz@state.sd.us
Carol Smith
carol.smith@state.sd.us

SECRETARIES

Beth Windschitl
beth.windschitl@state.sd.us
Rhea Kontos
rhea.kontos@state.sd.us

PDMP ASSISTANT

Melanie Houg
melanie.houg@state.sd.us

EXECUTIVE DIRECTOR

Kari Shanard-Koenders
kari.shanard-koenders@state.sd.us

BOARD OF PHARMACY

605-362-2737 | 605-362-2738 fax
www.pharmacy.sd.gov

PDMP DATA ACCESS

<https://southdakota.pmpaware.net/login>

PDMP DATA SUBMITTERS

<https://pmpclearinghouse.net/>

NATIONAL ASSOCIATION OF BOARDS OF PHARMACY

www.NABP.pharmacy



SDSU COLLEGE of PHARMACY and ALLIED HEALTH PROFESSIONS

= Jane Mort // Dean & Professor, College of Pharmacy & Allied Health Professions =



Holiday Greetings from the College of Pharmacy and Allied Health Professions as we welcome in 2020!

During this holiday season we take the opportunity to reflect on the many wonderful gifts we have received, and I want to express my deep appreciation for your support of the College. Our achievements would not be possible without your support.

Once again our 2019 PharmD graduates exceeded the national average on the NAPLEX. For our graduates who took the NAPLEX this summer, 97.4% passed on the first attempt (74/76), compared to the national first time pass rate of 90.6%. In addition, the average score for SDSU graduates was 102.48 compared to 96.80 nationally. As we reflect back over the last 16 years of NAPLEX results (2003 through 2018), SDSU has the highest first-time pass rate in the nation at 99.24%.

Our students have also distinguished themselves nationally. Specifically, P4 students - Philip Jacobson, Hannah Brokmeier, and Zach Muller - participated in the American College of Clinical Pharmacy, Clinical Pharmacy Challenge. From a field of 120 colleges, this team was among the top eight in the nation which qualified them for the final competition in New York City. In addition, Alexis Nyberg, a P4 Student, was selected to provide an APhA PharmTalk. This is a tremendous honor because it is rare for a P4 student to have the opportunity to present a PharmTalk. Typically these presentations are led by practitioners or residents. Finally, P4 student Chris Kotschevar was selected for the 2019-2020 PQA-CVS Health Foundation Scholars Program which includes his project focused on increasing awareness of the pharmacists' role. These are just a few examples of the outstanding work of our students.

This fall we had the privilege of honoring Dr. Komal Raina as our inaugural Kevin and Lorie Haarberg Cancer Research Chair through an investiture ceremony. Dr. Raina is the third endowed faculty member in the college and the 21st in the university. Along with this wonderful celebration, we also were able to renovate a portion of Avera North to add 420 square feet to our research space. This was also made possible through the generosity of the Haarbergs which provided matching funds for a state grant. Our research enterprise is truly taking off, in no small part from the generosity of our alumni that is transforming our faculty and our space.

I also want to share a bit about the new additions to our faculty and staff. This fall, Dr. Yen-Ming Huang joined the College as a pharmacy administration faculty member in the Department of Allied and Population Health. Dr. Aaron Hunt was also hired into the Department of Allied and Population Health as the coordinator for the Master of Public Health. Michelle Johnson joined the Department of Pharmaceutical Sciences as the program assistant. Scott Crane began at the SDSU Foundation in November as our new development director for the college. Each of these new members brings a special set of skills that will help us excel in new ways.

I wish you all the best in the coming year!

JANE MORT, PHARMD

Dean & Professor
College of Pharmacy & Allied Health Professions

SDSU's Student Collaboration for the Advancement and Promotion of Pharmacy

Natalie Sovell // SCAPP/APhA-ASP SDSU Chapter President



Greetings from SCAPP! Our organization has accomplished quite a bit in the past few months. In January, just over 30 students traveled to Pierre for the annual Legislative Days screenings. Many students were appreciative for the legislative update from SDPhA and were grateful for the chance to meet with legislators. Thank you to SDPhA for providing us with this opportunity!

Pharmaceutical Students Federation co-chairs teamed up with the American Association of Pharmaceutical Sciences organization and the Fundraising Committee to host a potluck and auction. Students and faculty members were able to sign up to bring a dish that was special to them. Auction items were donated from local businesses and faculty members. Funds from the auction will be used to purchase new cholesterol machines for screenings and for event programming. Our Service Committee co-chairs are hosting a blood drive with HEROH, another SDSU organization, in April. Additionally, students are able to participate in the pharmacy State-A-Thon team. Our SDPhA liaisons have recently been promoting our More Than A Count campaign to increase awareness of the roles of a pharmacist and the different types of pharmacy careers. Stay tuned for more posts from our liaisons on the More Than A Count Facebook page!



We have also elected our executive board for the 2020-2021 academic year and sent out applications for committee co-chair positions. SCAPP will have around 40 students leading our organization. Next year's presidents will be Anna Mohr (SCAPP/APhA-ASP), Grace Goehring (NCPA), Brittany Rhyner (PPA), Kjersten Sankey (SCCP), and Dustin Moon (SSHP). Additionally, we are excited to introduce a new vaping cessation committee, as this is a prevalent issue for college students.

Our organization has been working hard to plan events for our students and the community. We have continued to host screenings in Brookings at Lewis and at the Harvest Table and in Sioux Falls at the Banquet Ministry. We have hosted a couple ice cream fundraisers at Stensland Family Farms in Sioux Falls to help raise money for patient care screening supplies. At the end of February, our International



We hosted a local patient counseling competition and our winner was a second-year student pharmacist and our Brookings patient care coordinator, Mariah Burggraff. We are excited to have Mariah represent SDSU in the APhA-ASP National Patient Counseling Competition!

As president, I could not be more proud of what my organization has accomplished this past year! I am grateful for the opportunity to share with you what we have been up to!

Respectfully,

NATALIE SOVELL

SCAPP/APhA-ASP SDSU Chapter President 2019-2020



The Medication Learning Company
Update. Inform. Educate.™

PHARMACY TECHNICIANS UNIVERSITY

THE BEST-IN-CLASS TRAINING PROGRAM FOR PHARMACY TECHS

Take the headache out of technician training with the No. 1 provider of online learning. Simplify the educational experience, improve efficiency, and help reduce medication errors with *Pharmacy Technicians University (PTU)*.

TRAINING PROGRAM BENEFITS FOR TRAINEES

- * Easy to manage progress by staff with PTU administrator dashboards.
- * Scalable to meet each state's changing regulation through 4 scalable offerings for your different locations' requirements
- * PTU 101 provides 30 hours of dedicated hospital technician focus hours
- * Choose training program options with fewer hours for completion to limit impact on productivity
- * Faster path to increased staffing ratios for technicians in those states allowing increased ratios

Today, pharmacy technicians are increasingly important members of the pharmacy team. Skilled pharmacy technicians are critical for the economic and efficient function of a pharmacy. However, training requirements for pharmacy technicians change often and are becoming more complex, creating a shortage of qualified pharmacy technicians.

Pharmacy Technicians University (PTU) offers:

- * Programs ranging from 80 to 600 hours of didactic, simulation, and experiential learning
- * The highest quality technician training resources in a variety of learning modalities
- * The only online tech training program that supports or exceeds the requirements for technician training in 50 states, including Washington D.C.

CONTACT US:
<http://trchealthcare.com/contact-us>

pharmacy
technicians
university

WHY TECHNICIANS LOVE *PHARMACY TECHNICIANS UNIVERSITY*:

Current Course Curriculum reflects the latest industry trends and complies with state and national regulations.

Practice Skills with Feedback Features that allow techs to observe techniques, practice offline, and self-record demonstration of techniques.

Remote Instructors review tech demonstrations and provide one-to-one feedback.

Motivating Scenario Simulations give techs context for active learning and problem solving via "real-life" scenarios that facilitate appropriate information transfer and recall.

Innovative Course Design helps technicians learn while developing observational and critical thinking skills.

Engaging Content (including interactive exercises, learning games, and videos) is intermixed with didactic content to accommodate different learning styles.

TRC Healthcare
3120 W March Ln., Stockton CA 95219
209-472-2240
mail@pletter.com
TRCHealthcare.com

THE RIGHT SOLUTION FOR YOUR TECHNICIANS

The *Pharmacy Technicians University* training platform is the first web-based learning and education solution to support the diverse requirements for pharmacy technician training across all 50 states. Using a unique combination of technology and tools, *Pharmacy Technicians University* facilitates and tracks hands-on learning conveniently online.

PTU 101, PTU ADVANCED, AND PTU NATIONAL STANDARDS PHARMACY TECHNICIAN TRAINING FOR:

- * Provider and hospital settings
- * Retail and community settings
- * Health and wellness institutions such as long-term care and physical therapy centers

TAILORED CURRICULUM TO MEET YOUR ORGANIZATIONAL NEEDS

- * "Right-sized" curriculum, program components, and practice setting-specific courses
- * National Standards (ASHP/ACPE) program to meet state-specific compliance requirements
- * ACE Credit recommendation of 7 college level credit hours
- * Convenient, cost-effective online courses, including real-world scenarios, instructor feedback, and rich media content

FLEXIBLE OPTION PACKAGES



CONTACT US:
<http://trchealthcare.com/contact-us>

© 2017 Therapeutic Research Center (TRC) All Rights Reserved. TRC™ and associated TRC product marks included in this document (TM) are trademarks of Therapeutic Research Center. Rev 8/04/17


CORONAVIRUS (COVID-19) UPDATE FROM PTCB

As the coronavirus (COVID-19) situation continues to evolve, PTCB is here to support you and keep you informed.

MARCH 13, 2020 // UPDATED MARCH 27, 2020

For those who have applied and/or have scheduled to test:

- Effective March 17, Pearson VUE has suspended test delivery at its company-owned US and Canada-based testing centers for at least 30 days until April 16, or whenever conditions are deemed safe to reopen.
- If you have a scheduled appointment to test during this time, you will be able to reschedule your exam appointment based on test center availability. Pearson VUE will send a cancellation email with information on rescheduling your exam.
- If your Authorization to Schedule (ATS) is still valid, you may use the same ATS. If your ATS expires during the COVID-19 closures, PTCB will work with you to extend your ATS after the testing centers reopen. Eligibility will not be extended until we know when Pearson VUE test centers are opening again. We are aware there may be capacity issues when they do reopen and will work through these issues.
- Check the [Pearson VUE Coronavirus Update Page](#) regularly for the most current information on test delivery status, scheduling, and any policy changes.
- If you are authorized to take a PTCB Assessment-Based Certificate Exam in Technician Product Verification (TPV) or Medication History and would like to extend your exam authorization date due to COVID-19, please submit a [help request](#).
- If you applied for CPhT Certification before January 1, 2020 and were scheduled to take the 2019 version of the Pharmacy Technician Certification Exam (PTCE), you will still be able to take the 2019 version after your authorization is extended unless you withdraw your application.



- If your state requires pharmacy technicians to attain national certification as a condition of registration/licensure, we encourage you to check with your State Board of Pharmacy or regulating agency to determine your state's response to COVID-19.

For recertification candidates:

- We have extended recertification deadlines for 60 days for CPhTs and Compounded Sterile Preparation Technicians (CSPTs) who have March 31, April 30, and May 31 expiration dates to allow extra time for completing CE and submitting applications.
- Visit our [Continuing Education \(CE\) Directory](#), newly launched during this time to allow technicians to quickly find free CE programs and complete CE more easily. All CE programs listed are ACPE-accredited and free of charge. CE providers can visit the page to submit their free programs to be added to the directory.

Need other help? If you have questions about how COVID-19 is affecting your credentialing activities, please visit our help center at ptcb.org/help for frequently asked questions or to submit a help request.

SD Association of Pharmacy Technicians

John Thorns // SDAPT President

Greetings from SDAPT!

Our annual conference and CE day was held on Saturday October 5th, 2019. With the help of DDN Network we were live in three locations, Sioux Falls, Rapid City and Pierre. We look forward to continue holding this conference in these three locations and towards more growth within our organization.

At this conference new members were elected. John Thorns President, Cheryl Valburg Vice President, Dawn Swaney Treasurer, Julie Kulesza Secretary. Also books were balanced and an audit for 2019 passed.

Our pharmacy technicians received 6 CE's that day. The required Law and Safety course was presented by the SD Board Of Pharmacy Director Kari Shanard-Koenders. Spencer Lehman RPh presented on Safety-Chemotherapy drugs, containment and decontamination. Travis Anderberg RPh presented on the Technicians Role in retail pharmacy. Sioux Falls DCI presented on Trends of Not So Legal Drug Activities. Kristen Carter RPh presented on Thyroid. Lastly techs earned CE's from our SDAPT business meeting.

The SDAPT Scholarship winner was Brianna Kremppes, a student from South East Technical Institute in Sioux Falls. Brianna is hard working and has a lot going on all at once, but she does it all to achieve goals. She is pushing towards a better and happier future. Her \$250 scholarship was paid directly to her. A big thank you the committee members Sue DeJong, Debborah Cummings, Sandy Millar and Alicia Bauer for selecting our winner.

The association is currently working on securing a location and speakers for our 2020 conference. We are trying to expand our social media presence in hopes to reach out and get more members for the association.

Thank you for SDSHP for their generous sponsorship again this year, along with our other sponsors SDAPT, Avera and Rapid City Regional.

Appreciatively,
JOHN THORNS
SDAPT President



Have you ever wondered how your Well-Being compares to others? Consider investing six minutes in your well-being. The Well-Being Index is a brief online self-assessment, invented by the Mayo Clinic and brought to you through a partnership with the American Pharmacists Association (APhA), which provides you immediate individualized feedback including tools and local and national resources to address your well-being. You can set-up the frequency you wish to assess your well-being and track your progress.

Your information and score are private and your individual score will not be shared with APhA or anyone else. You do not have to be an APhA member to participate.

TAKE THE SURVEY NOW
IN A FEW EASY STEPS:

1. Go to: www.mywellbeingindex.org/signup
2. If asked for a participation code, use APhA
3. Register (approx. 3 minutes)
4. Take the survey (approx. 3 minutes)

South Dakota SOCIETY of HEALTH- SYSTEM PHARMACISTS

Joseph Berendse, PharmD, BCPS, BCACP // SDSHP President



Greetings from the South Dakota Society of Health-System Pharmacists!

I think the theme for SDSHP for 2020 so far has been embracing flexibility. The novel coronavirus pandemic has us again looking at a significant adjustment to the delivery of our hallmark event: the SDSHP Annual Conference. Our fortune is that because of the events of last year, we

are prepared to handle some of the complexities that a disruption of this magnitude brings with it. Hopefully, all those in attendance will embrace flexibility alongside us as we strive to deliver high-quality CE to our members despite the circumstances.

44th SDSHP Annual Conference

The 44th Annual SDSHP Conference is scheduled to take place on April 3rd-4th, 2020 at the Holiday Inn City Centre in Sioux Falls, SD. Unfortunately, because of concerns regarding COVID-19, we are looking at hosting a “virtual conference” as a back-up option. We hope you can join us – either in-person or digitally – for two days of great continuing education programming and networking! We are also thrilled to announce that ASHP CEO, Paul W. Abramowitz, PharmD, ScD. (Hon.), FASHP, is planned to join us as our keynote speaker. He will be speaking on the topic of leadership within pharmacy. Please visit www.sdsph.com for the most up-to-date information regarding the meeting format, and to register for the conference!

Winter Resident CE Events

SDSHP sponsored three CE events early this year for its members to attend. Each event featured residents from the various health-systems across South Dakota. The pharmacy residents delivered high-quality CE on a wide variety of topics – with the addition of a couple new PGY-2 programs since last year, we enjoyed an even greater diversity in subjects. These events took place on January 18th and

February 15th in Sioux Falls, and on February 22nd in Rapid City. SDSHP would like to extend a special thank you to the residents for their hard work in providing outstanding CE to our membership!

The 8th Annual SDSHP Statewide Residency Conference will be held again this summer. The date has not been established yet, but the conference will continue to provide an opportunity for residents to network and gain knowledge on topics that will benefit them during residency. I would like to thank Khia Warzecha – our resident liaison – who has been working diligently to prepare another memorable year of programming.

A Message of Thanks

With my term as SDSHP President coming to a close, I wanted to share some words of thanks. I am incredibly grateful to have worked with the 2019-2020 Board of Directors. Their dedication to SDSHP is what enables our organization to push forward and expand pharmacy services across South Dakota. I want to particularly thank our outgoing board members: Aaron Larson, Anna Delzer, Rose Fitzgerald, and Alyssa Boesche (student liaison). Thank you for all you have done and for serving the members of SDSHP!

During the next year, we will continue to serve health-system pharmacists and technicians under the exceptional leadership of Haylee Allen!

Respectfully submitted,

JOSEPH BERENDSE

PharmD, BCPS, BCACP
SDSHP President 2019-2020

2019/2020 COMMERCIAL & LEGISLATIVE DISTRICT DUES CONTRIBUTIONS

FIRST NAME _____ LAST NAME _____

ADDRESS _____

CITY _____ STATE _____ ZIP CODE _____

HOME PHONE _____ MOBILE PHONE _____

EMPLOYER / COMPANY _____

WORK ADDRESS _____

WORK CITY _____ STATE _____ ZIP CODE _____

WORK PHONE _____ WORK FAX _____

EMAIL ADDRESS _____

Do you wish to receive SDPhA email alerts regarding important pharmacy issues? YES NO

2019/2020 COMMERCIAL & LEGISLATIVE FUND

Memberships set by SDPhA C & L Executive Committee, 2007

PHARMACY OR BUSINESS MEMBERSHIP \$100.⁰⁰

Includes One Individual Membership

NAME OF PHARMACY / BUSINESS _____

NAME OF INDIVIDUAL INCLUDED _____

CORPORATE MEMBERSHIP \$200.⁰⁰

Two or more stores of the same corporation

NAME OF CORPORATION _____

NAME OF INDIVIDUAL INCLUDED _____

INDIVIDUAL MEMBERSHIP

\$50 LEVEL \$75 LEVEL OTHER \$ _____

DISTRICT DUES

Circle your District

ABERDEEN – \$20.⁰⁰ BLACK HILLS – \$20.⁰⁰ HURON – \$10.⁰⁰ MITCHELL – \$10.⁰⁰ MOBRIDGE – \$10.⁰⁰
ROSEBUD – \$10.⁰⁰ SIOUX FALLS – \$20.⁰⁰ WATERTOWN – \$20.⁰⁰ YANKTON – \$15.⁰⁰

TOTAL ENCLOSED

\$ _____

MAIL TO: SD PHARMACISTS ASSOCIATION, BOX 518, PIERRE, SD 57501-0518 / FAX: 605-224-1280



≡ 134th ANNUAL CONVENTION ≡

SD PHARMACISTS ASSOCIATION

➔ Registration available online at www.sdpha.org

Name _____

Address _____

City / State / Zip _____

Business Name _____

Business Address _____

Business City / State / Zip _____

Business Phone _____

Home Phone _____

Email _____

Spouse / Guest Name _____

eProfile ID: _____

Call 605-697-5232 for Hotel Reservations:

Hampton Inn & Suites
 3017 Lefevre Drive, Brookings, SD 57006
 Request South Dakota Pharmacists Association Block

Convention Registration Cancellation Policy:

- Cancellations will be accepted without penalty prior to September 1, 2020.
- A \$25 fee will be applied to all cancellations after September 1, 2020.
- Refunds will be issued after October 1, 2020.



All SDSU Student Registrations are FREE!

Hotel not included. Registration must be submitted prior to September 1, 2020.

Full Registration*

	SDPhA Member	Spouse or Guest	Children	SDAPT Member	Pharmacy Technician	Pharmacy Student	Non-SDPhA Member	
Before August 21, 2020	\$150	\$75	\$20	\$75	\$125	Free	\$225	\$ _____
After August 21, 2020	\$175	\$100	\$20	\$100	\$140	Free	\$250	\$ _____

1-Day Registration**

	SDPhA Member	Spouse or Guest	Children	SDAPT Member	Pharmacy Technician	Pharmacy Student	Non-SDPhA Member	
Friday, September 25, 2020	\$100	\$50	\$10	\$50	\$90	Free	\$150	\$ _____
Saturday, September 26, 2020	\$50	\$50	\$10	\$50	\$50	Free	\$75	\$ _____

Extra Tickets

	SDPhA Member	Spouse or Guest	Children	SDAPT Member	Pharmacy Technician	Pharmacy Student	Non-SDPhA Member	
Friday Lunch	\$15	\$15	\$10	\$15	\$15	Free	\$15	\$ _____
Saturday Breakfast	\$15	\$15	\$10	\$15	\$15	Free	\$15	\$ _____

I would like to sponsor a student. I have included an additional gift of \$ _____

I would like to contribute to the SDPhA Commercial & Legislative Fund.

I have included an additional amount of \$ _____

Total Due \$ _____

* Full Registration includes all educational sessions, exhibits, meals and evening events.

** 1-Day Registration includes educational sessions, exhibits, meals, and evening event, if applicable.

Please send payment and registration to:
South Dakota Pharmacists Association, PO Box 518, Pierre, SD 57501
 Tax ID#: 46-019-1834

Pharmacist Consult: FDA – What You Need to Know About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD

Knowledge-based CPE

Course Sponsorship: This course is sponsored by the South Dakota State University College of Pharmacy and Allied Health Professions, Brookings, SD

Course Development: The following material was published by the Food and Drug Administration (FDA): “What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD” Content is current as of 11-25-2019.

Permission has been granted by the FDA for the use of this material in Continuing Pharmacy Education for pharmacists.

GOAL: To enhance pharmacists’ knowledge of cannabis and related compounds.

LEARNING OBJECTIVES:

1. Explain the regulatory status of CBD-related products;
2. Describe three potential CBD-related health risks that have been identified by the FDA;
3. Identify currently recognized CBD side effects;
4. Review the various forms of products in the market place that contain CBD;
5. Counsel patients on FDA safety concerns and false claim advisories related to CBD.

What You Need to Know (and What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD



The FDA is working to answer questions about the science, safety, and quality of products containing cannabis and cannabis-derived compounds, particularly CBD.

- The FDA has approved only one CBD product, a prescription drug product to treat two rare, severe forms of epilepsy.
- It is currently illegal to market CBD by adding it to a food or labeling it as a dietary supplement.
- The FDA has seen only limited data about CBD safety and these data point to real risks that need to be considered before taking CBD for any reason.
- Some CBD products are being marketed with unproven medical claims and are of unknown quality.

The FDA will continue to update the public as it learns more about CBD.

1. CBD has the potential to harm you, and harm can happen even before you become aware of it.
 - CBD can cause liver injury.
 - CBD can affect the metabolism of other drugs, causing serious side effects.
 - Use of CBD with alcohol or other Central Nervous System depressants increases the risk of sedation and drowsiness, which can lead to injuries.

2. Use of CBD with alcohol or other Central Nervous System depressants increases the risk of sedation and drowsiness, which can lead to injuries.
 - CBD can cause side effects that you might notice. These side effects should improve when CBD is stopped or when the amount ingested is reduced.
 - Changes in alertness, most commonly experienced as somnolence (drowsiness or sleepiness).
 - Gastrointestinal distress, most commonly experienced as diarrhea and/or decreased appetite.
 - Changes in mood, most commonly experienced as irritability and agitation.
3. There are many important aspects about CBD that we just do not know, such as:
 - What happens if you take CBD daily for sustained periods of time?
 - What is the effect of CBD on the developing brain (such as children who take CBD)?
 - What are the effects of CBD on the developing fetus or breastfed newborn?
 - How does CBD interact with herbs and botanicals?
 - Does CBD cause male reproductive toxicity in humans, as has been reported in studies of animals?

You may have noticed that cannabidiol (CBD) seems to be available almost everywhere, and marketed as a variety of products including drugs, food, dietary supplements, cosmetics, pet food, and other animal health products.

The U.S. Food and Drug Administration (FDA) recognizes the significant public interest in cannabis and cannabis-derived compounds, particularly CBD. However, there are many unanswered questions about the science, safety, and quality of products containing CBD. The Agency is working on answering these questions through ongoing efforts including feedback from a recent [FDA hearing](#) and information and data gathering through a [public docket](#).

Despite the 2018 Farm Bill removing hemp - defined as cannabis and cannabis derivatives with very low concentrations (no more than 0.3% on a dry weight basis) of THC - from the definition of marijuana in the Controlled Substances Act, CBD products are still subject to the same laws and requirements as FDA-regulated products that contain any other substance.

The FDA is concerned that people may mistakenly believe that trying CBD “can’t hurt.” The agency wants to be clear that we have seen only limited data about CBD’s safety and these data point to real risks that need to be considered. As part of the drug review and approval process for the prescription drug containing CBD, it was determined that the risks are outweighed by the benefits of the approved drug for the particular population for which it was intended.

Consumer use of any CBD products should always be discussed with a healthcare provider. Consumers should be aware of the potential risks associated with using CBD products. Some of these can occur without your awareness, such as:

Liver Injury: During its review of the marketing application for [Epidiolex](#) - a purified form of CBD that the FDA approved in 2018 for use in the treatment of two rare and severe seizure disorders - the FDA identified certain safety risks, including the potential for liver injury. This serious risk can be managed when an FDA-approved CBD drug product is taken under medical supervision, but it is less clear how it might be managed when CBD is used far more widely, without medical supervision, and not in accordance with FDA-approved labeling. Although this risk was increased when taken with other drugs that impact the liver, signs of liver injury were seen also in patients not on those drugs. The occurrence of this liver injury was identified through blood tests, as is often the case with early problems with the liver. Liver injury was also seen in other studies of CBD in published literature. We are concerned about potential liver injury associated with CBD use that could go undetected if not monitored by a healthcare provider.

Drug Interactions: Information from studies of the FDA-approved CBD drug Epidiolex show that there is a risk of CBD impacting other medicines you take - or that other medicines you take could impact the dose of CBD that can safely be used. Taking CBD with other medications may increase or decrease the effects of the other medications. This may lead to an increased chance of adverse effects from, or decreased effectiveness of, the other medications. Drug interactions were also seen in other studies of CBD in published literature. We are concerned about the potential safety of taking other medicines with CBD when not being monitored by a healthcare provider. In addition, there is limited research on the interactions between CBD products and herbs or botanicals in dietary supplements. Consumers should use caution when combining CBD products with herbs or dietary supplements.

CONTINUING EDUCATION *for* PHARMACISTS

Pharmacist Consult: FDA – What You Need to Know About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD

Knowledge-based CPE

Male Reproductive Toxicity: Studies in laboratory animals showed male reproductive toxicity, including in the male offspring of CBD-treated pregnant females. The changes seen include decrease in testicular size, inhibition of sperm growth and development, and decreased circulating testosterone, among others. Because these findings were only seen in animals, it is not yet clear what these findings mean for human patients and the impact it could have on men (or the male children of pregnant women) who take CBD. For instance, these findings raise the concern that CBD could negatively affect a man's fertility. Further testing and evaluation are needed to better understand this potential risk.

In addition, CBD can be the cause of side effects that you might notice. These side effects should improve when CBD is stopped or when the amount ingested is reduced. This could include changes in alertness, most commonly experienced as somnolence (sleepiness), but this could also include insomnia; gastrointestinal distress, most commonly experienced as diarrhea and/or decreased appetite, but could also include abdominal pain or upset stomach; and changes in mood, most commonly experienced as irritability and agitation.

The FDA is actively working to learn more about the safety of CBD and CBD products, including the risks identified above and other topics, such as:

- **Cumulative Exposure:** The cumulative exposure to CBD if people access it across a broad range of consumer products. For example, what happens if you eat food with CBD in it, use CBD-infused skin cream and take other CBD-based products on the same day? How much CBD is absorbed from your skin cream? What if you use these products daily for a week or a month?

- **Special Populations:** The effects of CBD on other special populations (e.g., the elderly, children, adolescents, pregnant and lactating women).

CBD and Animals: The safety of CBD use in pets and other animals, including considerations of species, breed, or class and the safety of the resulting human food products (e.g., meat milk, or eggs) from food-producing species.

ACTIVE LEARNING QUESTION:

Name three commonly experienced CBD side effects.

-----, -----, -----.

Some CBD Products are Being Marketed with Unproven Medical Claims and Could be Produced with Unsafe Manufacturing Practices

Unlike the FDA-approved CBD drug product, unapproved CBD products, which could include unapproved drugs, cosmetics, foods, and products marketed as dietary supplements, have not been subject to FDA evaluation regarding whether they are effective to treat a particular disease or have other effects that may be claimed. In addition, they have not been evaluated by the FDA to determine what the proper dosage is, how they could interact with other drugs or foods, or whether they have dangerous side effects or other safety concerns.

Misleading, unproven, or false claims associated with CBD products may lead consumers to put off getting important medical care, such as proper diagnosis, treatment, and supportive care. For that reason, it's important to talk to your doctor about the best way to treat diseases or conditions with available FDA-approved treatment options.

In addition to safety risks and unproven claims, the quality of many CBD products may also be in question.

The FDA is also concerned that a lack of appropriate processing controls and practices can put consumers at additional risks. For example, the agency has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed. We are also investigating reports of CBD potentially containing unsafe levels of contaminants (e.g., pesticides, heavy metals, THC).

CBD products are also being marketed for pets and other animals. The FDA has not approved CBD for any use in animals and the concerns regarding CBD products with unproven medical claims and of unknown quality equally apply to CBD products marketed for animals. The FDA recommends pet owners talk with their veterinarians about appropriate treatment options for their pets.

The FDA's top priority is to protect the public health. This priority includes making sure that consumers know about products that put their health and safety at greatest risk, such as those claiming to prevent, diagnose, treat, mitigate, or cure serious diseases. For example, the agency has warned companies to stop selling CBD products they claim are intended to prevent, diagnose, treat, mitigate, or cure serious diseases such as cancer, Alzheimer's disease, psychiatric disorders and diabetes.

While we have focused on these types of products, we will continue to monitor the marketplace for any product that poses a risk to public health, including those with dangerous contaminants, those marketed to vulnerable populations, and products that otherwise put the public health at risk.

The FDA is Continuing to Evaluate the Regulatory Frameworks for Products Containing Cannabis and Cannabis- Derived Compounds

The FDA continues to believe the drug approval process represents the best way to ensure that safe and effective new medicines, including any drugs derived from cannabis, are available to patients in need of appropriate medical therapy. The agency is committed to supporting the development of new drugs, including cannabis and cannabis-derived drugs, through the investigational new drug and drug approval process.

We are aware that there may be some products on the market that add CBD to a food or label CBD as a dietary supplement. Under federal law, it is illegal to market CBD this way.

The FDA is evaluating the regulatory frameworks that apply to certain cannabis-derived products that are intended for non-drug uses, including whether and/or how the FDA might consider updating its regulations, as well as whether potential legislation might be appropriate. The information we have underscores the need for further study and high quality, scientific information about the safety and potential uses of CBD.

The FDA is committed to setting sound, science-based policy. The FDA is raising these safety, marketing, and labeling concerns because we want you to know what we know. We encourage consumers to think carefully before exposing themselves, their family, or their pets, to any product, especially products like CBD, which may have potential risks, be of unknown quality, and have unproven benefits.

Our Consumer Update includes a practical summary of what we know to date. As we learn more, our goal is to update you with the information you need to make informed choices about CBD products. Also, as the regulatory pathways are clarified we will take care to inform all stakeholders as quickly as possible.

DIRECTIONS:

Complete the answer sheet / evaluation on the following page and submit it for credit to:

The Office of Continuing Education, South Dakota State University College of Pharmacy and Allied Health Professions.
For additional information, call 605-688-4242

Disclosure: *The developer and reviewers of this course have no relevant financial relationships to declare.*

Pharmacist Consult: FDA – What You Need to Know About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD

Learning Assessment – Post-test Select all correct answers for each question

- Select the True statement(s) below:
 - The FDA has approved only one CBD product.
 - It is currently legal to market CBD as a dietary supplement.
 - It is currently legal to market CBD as a food additive.
 - All of the above are true.
- Following the 2018 Farm Bill provision removing hemp from the definition of marijuana in the Controlled Substances Act., CBD is _____ subject to the same laws and requirements as FDA-regulated products that contain any other substance.
 - still
 - no longer
- Information studies of the FDA-approved CBD drug Epidiolex have identified these three potential health risks that were determined to be associated with the use of that medication:
 - Kidney failure / increased seizures / diabetes
 - Female reproductive toxicity / nausea / paranoia
 - Drug interactions / psychoses / dysphagia
 - Liver injury / potential drug interactions / male reproductive toxicity
- The FDA has identified these CBD-related side effects (select all that apply):
 - Constipation, increased appetite
 - Drowsiness
 - Diarrhea, decreased appetite
 - Mood changes / irritability, agitation
- Cannabidiol (CBD) is being marketed as a variety of products including (select all that apply):
 - Pet food
 - Cosmetics
 - Dietary supplements
 - Food
- Liver injury has been identified as a potentially serious adverse effect of CBD use. These related concerns have been cited by the FDA:
 - Interactions with herbs or dietary supplements
 - Lack of monitoring by a healthcare provider
 - Lack of FDA approved labeling on unregulated products
 - All of the above
- The FDA has identified the following concerns related to potential CBD drug interactions:
 - Drug interactions have been identified in CBD studies in published literature
 - CBD may increase or decrease the effects of other medications
 - There is limited research on the interactions between CBD and herbs or dietary supplements
 - All of the above
- Laboratory animals have shown male reproductive toxicity, including in the male offspring of CBD-treated pregnant females. The changes seen have included _____.
 - Decrease in testicular size
 - Inhibition of sperm growth and development
 - Increase in circulating testosterone
 - None of the above
- The FDA is actively working to learn more about the safety of CBD and CBD products, including the potential risks associated with _____.
 - Absorption properties
 - Cumulative exposure
 - Effects on children
 - Effects on pregnant and lactating women
- Patients should be counseled about the potential consequences of _____ behind CBD marketing and advertising.
 - Unsafe manufacturing practices
 - Unproven medical claims
 - Contaminated CBD products
 - Delaying evidence-based medical treatments in favor of CBD use

Pharmacist Consult: FDA – What You Need to Know About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD

Knowledge-based CPE

To receive 1.0 Contact Hours (0.1 CEUs) of continuing education credit, preview and study the attached article and answer the 10-question post-test by circling the appropriate letter on the answer form below and completing the evaluation. A test score of at least 70% is required to earn credit for this course. If a score of 70% (7/10) is not achieved on the first attempt, another answer sheet will be sent for one retest at no additional charge.



The South Dakota State University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Program Identification number for this program is: #0063-0000-20-024-H03-P.

Learning Objectives - Pharmacists: 1. Explain the regulatory status of CBD-related products; 2. Describe three potential CBD-related health risks that have been identified by the FDA; 3. Identify currently recognized CBD side effects; 4. Review the various forms of products in the market place that contain CBD; 5. Counsel patients on FDA safety concerns and false claim advisories related to CBD.

Circle Correct Answer: 1. A B C D 2. A B C D 3. A B C D 4. A B C D 5. A B C D 6. A B C D 7. A B C D 8. A B C D 9. A B C D 10. A B C D

COURSE EVALUATION: must be completed for credit.

	DISAGREE							AGREE						
Material was effectively organized for learning:	1	2	3	4	5	6	7	1	2	3	4	5	6	7
Content was timely and applicable for re-licensing / recertification:	1	2	3	4	5	6	7	1	2	3	4	5	6	7
Each of the stated learning objectives was satisfied:	1	2	3	4	5	6	7	1	2	3	4	5	6	7

List any learning objectives above not met in this course: _____

List any important points that you believe remain unanswered: _____

Course material was evidence-based, balanced, noncommercial: 1 2 3 4 5 6 7

List any details relevant to commercialism: _____

Learning assessment questions appropriately measured comprehension 1 2 3 4 5 6 7

Length of time to complete course was reasonable for credit assigned 1 2 3 4 5 6 7

(Approximate amount of time to preview, study, complete and review this 1.0 hour CE course: _____)

Comments: List any future CE topics of interest (and related skill needs): _____

NAME: _____ RPH LICENSE #: _____

STREET: _____ CITY: _____ STATE: _____ ZIP: _____

EMAIL ADDRESS: _____ PH: _____ INTEREST IN ADDITIONAL CE COURSES? Y / N

e-PROFILE ID NUMBER (ePID): _____ DATE OF BIRTH (MMDD): _____

Course release date: March 2, 2020 / Expiration date: March 2, 2023 / Target audience: Pharmacists

Please mail this completed answer sheet with your check of \$8.00 to: SDSU College of Pharmacy-C.E. Coord. Box 2202C, Brookings, SD 57007 / Office Ph: 605-688-4242 / Bernie.Hendricks@sdstate.edu

TEAM OF THE YEAR AWARD

The Pharmacists Mutual Insurance Company 2019 Team of the Year Award was presented to the following Field Representatives: Wayne Brownstein (CA), Andrew Permann (MN), Ryan Goodrich (AZ/NM/NV), Amy Haugen (ND/SD), Anne Kelley (AK/WA), Ryan

Kraft (MN), Melissa McKean (NE/SD), David Davis (CA), Larry Mai (CA), Kristina Grimes (OR), Ryan Anderson (ID/UT), Kashira Brookhart (CA), Tom Quesenbery (CO).


This award recognized the team with the best overall ratings in

the categories of territory growth, new business, life insurance and retention of current business. Jeff Welp, Sales Team Leader, received this award at the 2020 Annual Sales Meeting.



Front row left to right: Wayne Brownstein (CA), Andrew Permann (MN), Ryan Goodrich (AZ/NM/NV), Amy Haugen (ND/SD), Anne Kelley (AK/WA), Ryan Kraft (MN) **Back row left to right:** Ed Yorty, President & CEO, Melissa McKean (NE/SD), Paul Luckman, SVP Sales & Marketing, David Davis (CA), Larry Mai (CA), Kristina Grimes (OR), Ryan Anderson (ID/UT)
Not pictured: Kashira Brookhart (CA), Tom Quesenbery (CO), Jeff Welp, Sales Team Leader

CONGRATULATIONS 2020 SCHOLARSHIP WINNERS



Pharmacists Mutual is proud to support students who are interested in serving in an independent or small chain community pharmacy or an underserved geographic or cultural community. Each student listed received a \$2,500 scholarship.

- AMNA PARACHA** University of Maryland Eastern Shore
- BENJAMIN HIGHTOWER** University of Georgia
- BROOKE HENRIKSEN** California Health Sciences University
- JADA JENSEN** University of Wyoming
- EMILY BRUNSON** University of Texas at Austin
- LAUREN BREWER** University of Georgia
- JOHNNY ALEXANDER** University of Texas at Austin
- JULIA ANNIS** University of Rhode Island
- KAYLA LELAND** Washington State University
- MICHAEL DANILOV** University at Buffalo

- MASON SYKES** Samford University
- MORGAN PLATTA** University of Wisconsin–Madison
- LESLIE VO** University of Texas at Austin
- ROBERTO NAVA** University of California–San Diego
- NEVIN RADECHEL** Drake University
- RAEANN KILGORE** University of Missouri–Kansas City
- SARAH HENDERSON** Virginia Commonwealth University
- STEPHANIE MARTIN** Drake University
- STEPHANIE LUKEVICH** South University
- BRIANNA SMITH** William Carey University



Pharmacists Mutual Insurance Company
808 Highway 18 W | PO Box 370 | Algona, Iowa 50511
P. 800.247.5930 | F. 515.295.9306 | E. info@phmic.com
phmic.com

**ACCEPTING APPLICATIONS
FOR 2021 SCHOLARSHIP**
October 1, 2020 - December 1, 2020
<https://www.phmic.com/scholarship/>

Classifieds

Classified Rates

Classified ads are \$25 per five line ad per issue. Additional lines will be billed at \$1 per line. Including your company logo will be an extra \$5 charge.

Place a Classified

To place a classified ad, please write, email, call or fax:
SD Pharmacist Classified, PO Box 518, Pierre, SD 57501
sdpha@sdpha.org | 605-224-2338 | 605-224-1280 *fax*

FOR SALE

Pharmacy antiques and collectibles. B-W Delft tiles, Glassware, graduates, glass stoppered bottles. Respond to emdeets@hotmail.com or phone 712-441-6141.